Frontiers in Oncology最新文献

{"title":"A bibliometric and visual analysis of Jak1 to explore trends and frontiers.","authors":"Cong Yu, Jiamin Cao, Xiaodong Xie, Wenguang Chen, Ensi Hong","doi":"10.3389/fonc.2025.1537508","DOIUrl":"https://doi.org/10.3389/fonc.2025.1537508","url":null,"abstract":"<p><strong>Background: </strong>JAK1, a member of the JAK kinase family, is involved in the signal transduction of multiple cytokine pathways and is crucial in the onset and progression of inflammation and tumours. Consequently, JAK1 has garnered significant attention in recent years.</p><p><strong>Methods: </strong>We use bibliometric and visual analysis to evaluate the thematic trends and knowledge structure of TRPV1's research papers on JAK1, sourced from the Web of Science core collection from 2003 to 2024. CiteSpace is used to analyze references and keywords of authors, institutions, countries, and commonly cited, and applies co-current and clustering functions to generate visual knowledge maps.</p><p><strong>Results: </strong>A total of 3,686 articles were incorporated. The primary research domain of JAK1 is oncology; the United States leads in publication volume, with the University of Texas holding the most prominent central position. The keyword distribution indicates that the literature on JAK1 from 2003 to 2009 primarily concentrated on mechanistic studies, encompassing gene expression, activation, pathways, and cell apoptosis. From 2008 to 2018, research hotspots predominantly examined the association between JAK1 and various disease atlases. Beginning in 2012 and extending to 2024, the focus shifted towards the research and development of clinical pharmaceuticals, along with their safety and efficacy. Gene expression, signal transduction, atopic dermatitis, and JAK1-selective inhibitors have emerged as prominent research areas in recent years, exhibiting significant potential for development.</p><p><strong>Conclusion: </strong>This study presents the contemporary status and prospective trends of JAK1 research over the last two decades. Current research focuses on skin inflammation, rheumatoid arthritis, and tumor-related diseases, while new signaling pathways are constantly being discovered. JAK1 inhibitors are gradually being used in clinical practice and have good development prospects, which will become the main trend of future research.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1537508"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should we focus on in pregnancy complicated by pheochromocytoma? a bibliometric analysis (1990-2024).","authors":"Shiyun Deng, Fan Li, Jing Tian, Congcong Sun, Yanqing Zhang","doi":"10.3389/fonc.2025.1557376","DOIUrl":"https://doi.org/10.3389/fonc.2025.1557376","url":null,"abstract":"<p><strong>Purpose of review: </strong>The incidence of pheochromocytoma and paraganglioma (PPGL) in pregnancy is extremely low, yet it poses a significant threat to maternal and fetal safety. While studies are published annually, progress in this field remains slow. A key question is how researchers can better utilize limited case data to gain valuable insights. This bibliometric review summarizes the current research landscape, highlights recent findings, and suggests areas for future investigations.</p><p><strong>Methods: </strong>A comprehensive search was conducted in the Web of Science Core Collection (WoSCC), PubMed, and Embase databases for PPGL in pregnancy from 1990 to 2024. Data analysis was performed using Excel 2022 and CiteSpace.</p><p><strong>Current state: </strong>A total of 391 articles were included in the analysis. The United States was the most prolific country, and the Mayo Clinic was the most productive institution. Lenders JWM was identified as both the most published and most co-cited author. <i>Journal of the Endocrine Society</i> was the most frequently targeted journal for publication, while the <i>Journal of Clinical Endocrinology & Metabolism</i> had the highest number of co-citations. Evidence-based practice in this field primarily depends on case reports, case series, case-control studies, and systematic reviews. The primary focus in this research area is on clinical management and pregnancy complications.</p><p><strong>Recent findings: </strong>Maternal and infant mortality in pheochromocytoma during pregnancy has significantly decreased due to improved awareness and advances in diagnosis and treatment. Antepartum diagnosis is the most vital element in reducing mortality; hypertension at admission and history of PPGL were independent factors of antepartum diagnosis. Abdominal/pelvic tumor location and catecholamine levels ≥10 times the upper limit of the reference range were associated with adverse outcomes. Women with hereditary disease and risk of developing PPGL should be screened before becoming pregnant for occult PPGL and should be treated adequately.</p><p><strong>Conclusion: </strong>Enhanced collaboration between countries and institutions is needed to advance the field. Diagnostic and therapeutic strategies, as well as complications associated with PPGL during pregnancy, have consistently been core areas of research. Future studies should prioritize the clarification of detailed clinical management protocols and the underlying pathophysiological mechanisms, with the goal of generating high-quality evidence to guide the care of this high-risk population.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1557376"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Cardiac myxoid fibrosarcoma: a report of two cases.","authors":"Weikai Dong, Zhaoqi Du, Dianxiao Liu, Lijuan Yang, Wei Li","doi":"10.3389/fonc.2025.1567625","DOIUrl":"https://doi.org/10.3389/fonc.2025.1567625","url":null,"abstract":"<p><strong>Introduction: </strong>The research into cardiac tumors can be traced back to the 18th century, when Bonet first introduced the relevant concept. It was not until 1936 that the first successful resection of a cardiac tumor was performed. From a pathological origin perspective, cardiac tumors can be categorized into two main types: primary tumors, which originate from the heart itself, and secondary tumors, which result from metastases of malignant tumors in other tissues or organs. Primary cardiac tumors are exceedingly rare, among primary cardiac tumors, roughly 75% are benign, while the remainder are malignant. In contrast, approximately 75% of primary malignant cardiac tumors are sarcomas. Cardiac myxoid fibrosarcoma stands out as a particularly rare diagnosis in this domain.</p><p><strong>Case report: </strong>Case one: A 25-year-old man presented with chest pain and tightness. After initial treatment, his symptoms recurred and worsened. Imaging revealed a large mass in the left atrium obstructing the mitral valve. He underwent surgical resection of the tumor, thrombectomy, and tricuspid valvuloplasty. Pathology diagnosed myxoid fibrosarcoma. The patient was readmitted 7 months later with hemoptysis due to tumor recurrence and was lost to follow-up after symptomatic treatment. Case two: A 67-year-old woman was admitted with cough, chest tightness, and shortness of breath. Physical examination and imaging showed a mass in the left atrium causing mitral valve obstruction. She underwent surgical resection of the tumor. Pathology confirmed myxoid fibrosarcoma. After 6 months of follow-up, there was no tumor recurrence or metastasis.</p><p><strong>Discussion: </strong>Myxoid fibrosarcoma located in the left atrium can lead to mitral valve obstruction, causing symptoms of mitral stenosis such as dyspnea, cough, hemoptysis, and reduced exercise tolerance. Surgery remains the primary treatment for primary left atrial malignant tumors. Once the diagnosis is confirmed, active surgical intervention should be performed to relieve blood flow obstruction, remove pericardial effusion, and alleviate cardiac compression, which can extend patients' lives in the short term and improve their quality of life. Despite advancements in diagnostic techniques and surgical methods, the prognosis for patients with cardiac tumors still depends on the histology and location of the tumor.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1567625"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Malignant transformation of maxillary giant cell tumor of bone from EURACAN reference center.","authors":"Federica Riva, Sabrina Vari, Concetta Elisa Onesti, Renato Covello, Silvia Scuderi, Serena Ceddia, Maria Rosaria Fiore, Vincenzo Anelli, Sabino Strippoli, Virginia Ferraresi","doi":"10.3389/fonc.2025.1604056","DOIUrl":"https://doi.org/10.3389/fonc.2025.1604056","url":null,"abstract":"<p><p>Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm that can rarely undergo malignant transformation, with a poor prognosis. The most frequent histotypes of the sarcomatous transformation of GCTB are osteosarcoma, fibrosarcoma, and undifferentiated pleomorphic sarcoma, and the treatment approach mirrors that of high-grade sarcomas. This case report describes the malignant transformation of a maxillary GCTB treated with standard systemic treatments for bone tumors and local treatment, resulting in a progression of disease until the patient's death. Nevertheless, a marked radiological and clinical response was achieved with local carbon ion therapy. This case highlights the diagnostic and therapeutic challenges of malignant transformation of GCTB, emphasizing the importance of a multidisciplinary approach at specialized centers and the potential role of local therapies in selected cases.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1604056"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases.","authors":"Hai-Zhen Yi, Wei Lv, Jin-Jing Chen, Zhan Lin","doi":"10.3389/fonc.2025.1545101","DOIUrl":"https://doi.org/10.3389/fonc.2025.1545101","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the efficiency and safety of Cadonilimab and Anlotinib pairing in individuals diagnosed with small cell lung cancer (SCLC) and brain metastases (BMs).</p><p><strong>Methods: </strong>A review was performed on individuals who were diagnosed with small cell lung cancer (SCLC) and had central nervous system (CNS) metastases confirmed via magnetic resonance imaging (MRI) of the brain.We assessed the treatment response of Cadonilimab plus Anlotinib using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Response assessment in neuro-oncology brain metastases (RANO-BM) for evaluating solid tumors and neuro-oncology brain metastases, respectively.The patients' prognosis was determined using Kaplan-Meier analysis and Cox regression analysis.</p><p><strong>Findings: </strong>The study initially included 46 patients diagnosed with SCLC who presented with brain metastases (BMs). According to the RANO-BM criteria, intracranial lesions showed an objective response rate (ORR) of 41.3%. The median overall survival (OS) was observed to be 19.3 months (95% CI, 17.4-21.1 months). Multivariate Cox regression analysis showed that having a PD1 level below 50% (HR=4.83, <i>P <</i>0.001) or having two or more metastatic organs (HR = 2.71, <i>P</i> = 0.036) were independent factors that positively predicted overall survival of all the patients, 86.9% experienced treatment-related adverse events (TRAEs) associated with the treatment, while 17.4% reported severe TRAEs of grade3-4.</p><p><strong>Implications: </strong>According to our results, the combination of Cadonilimab and Anlotinib appears to be a promising treatment option for SCLC patients with brain metastases.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1545101"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER.","authors":"Xiaomeng Di, Xiaohong Shi, Feng Gai, Jiawei Wang","doi":"10.3389/fonc.2025.1621045","DOIUrl":"https://doi.org/10.3389/fonc.2025.1621045","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitor (ICI)-associated neurological immune-related adverse events (NAEs) are rare but serious side effects, of which autoimmune encephalitis (AIE) is a potentially fatal central nervous system disorder requiring more attention.</p><p><strong>Methods: </strong>We performed a retrospective disproportionality analysis of NAE reports in the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Event Reporting Database (JADER) from 2004 to 2024, utilizing reporting odds ratio (ROR), proportional reporting ratio (PRR), the Bayesian confidence propagation neural network BCPNN, and the multi-item gamma Poisson shrinker (MGPS) for signal detection.</p><p><strong>Results: </strong>In total, 3,999 reports of ICI-associated NAEs were identified from the FAERS database, of which 1,998 reports were AIE. 1,558,251 reports of AEs were collected from the JADER database, which contained 890 AIE reports. ICIs, including pembrolizumab, nivolumab, atezolizumab, ipilimumab, and durvalumab, were identified among the top 30 agents in both databases, demonstrating significant signals across all 4 algorithms. Except for noninfectious myelitis, acute disseminated encephalomyelitis, and multiple sclerosis, positive signals were detected in all other preferred terms (PTs). These NAEs accounted for 23.7% of total mortality, with myasthenia gravis (MG) exhibiting the highest mortality rate at 30.63%. Specific PTs, such as aseptic meningitis, AIE, chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barré syndrome, MG, myelitis, and immune-related myopathy, were associated with the severity of outcomes, showing significant statistical differences between severe and non-severe cases (p < 0.05).</p><p><strong>Conclusion: </strong>Our study found a notable correlation between ICIs and AIE and other specific NAEs, highlighting the demographic characteristics, time to onset, and disease severity of ICI-induced NAEs, thereby facilitating the timely recognition and treatment of these ICI therapy-related complications.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1621045"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Molecular pigeon\" network of lncRNA and miRNA: decoding metabolic reprogramming in patients with lung cancer.","authors":"Mingxiao Li, Ling Dai, Simin Chen, Minjie Deng, Lihuai Wang, Yinhui Sun","doi":"10.3389/fonc.2025.1578927","DOIUrl":"https://doi.org/10.3389/fonc.2025.1578927","url":null,"abstract":"<p><p>In recent years, with the advancement of RNA analysis techniques, such as single-cell RNA sequencing, noncoding RNAs have demonstrated substantial potential in regulating gene expression, encoding peptides and proteins, constructing the cellular microenvironment, and modulating cell function. They can serve as potential therapeutic targets and diagnostic markers for various diseases, offering novel avenues for diagnosis and treatment. Among them, long noncoding RNAs (lncRNAs) represent a principal component. Through the competing endogenous RNA mechanism, lncRNAs sequester microRNAs (miRNAs), interact with metabolic enzymes or transcription factors, regulate gene expression, and participate in the metabolic communication network within the tumor microenvironment. This process significantly promotes the growth, proliferation, and metastasis of lung cancer cells by reprogramming core metabolic pathways-including glucose utilization, lipid homeostasis, and amino acid flux. This article reviews the key roles of lncRNAs and miRNAs in the metabolic reprogramming of patients with lung cancer, elucidates the complex lncRNA-miRNA network involved, and provides mechanistic insights into metabolic vulnerabilities and translational opportunities for targeted interventions in the diagnosis and treatment of lung cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1578927"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLGB-Net: fusion network for identifying local and global information of lesions in digital mammography images.","authors":"Ningxuan Hu, Zhizhen Gao, Zongyu Xie, Lei Li","doi":"10.3389/fonc.2025.1600057","DOIUrl":"https://doi.org/10.3389/fonc.2025.1600057","url":null,"abstract":"<p><p>Worldwide, breast cancer ranks among the cancers with the highest incidence rate. Early diagnosis is crucial to improve the survival rate of patients. Digital Mammography (DM) is widely used for breast cancer diagnosis. The disadvantage is that DM relies too much on the doctor's experience, which can easily lead to missed diagnosis and misdiagnosis. In order to address the shortcomings of traditional methods, a CLGB-Net deep learning model integrating local and global information is proposed for the early screening of breast cancer. Four network architectures are integrated into the CLGB-Net model: ResNet-50, Swin Transformer, Feature Pyramid Network (FPN), and Class Activation Mapping (CAM). ResNet-50 is used to extract local features. The Swin Transformer is utilized to capture global contextual information and extract global features. FPN achieves efficient fusion of multi-scale features. CAM generates a class activation weight matrix to weight the feature map, thereby enhancing the sensitivity and classification performance of the model to key regions. In breast cancer early screening, the CLGB-Net demonstrates the following performance metrics: a precision of 0.900, recall of 0.935, F1-score of 0.900, and final accuracy of 0.904. Experimental data from 3,552 samples, including normal, benign, and malignant cases, support these results. The precision of this model was improved by 0.182, 0.038, 0.023, and 0.021 compared to ResNet-50, ResNet-101, Vit Transformer, and Swin Transformer, respectively. The CLGB-Net model is capable of capturing both local and global information, particularly in terms of sensitivity to subtle details. It significantly improves the accuracy and robustness of identifying lesions in mammography images and reduces the risk of missed diagnosis and misdiagnosis.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1600057"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.","authors":"Keisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, Taiga Otsuka, Toshimitsu Tanaka, Masaru Fukahori, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Toshihiro Fujita, Takahiro Sakae, Yasunori Kawaguchi, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi","doi":"10.3389/fonc.2025.1626689","DOIUrl":"https://doi.org/10.3389/fonc.2025.1626689","url":null,"abstract":"<p><strong>Introduction: </strong>The significance of third-line chemotherapy (CTx) in unresectable pancreatic cancer (UPC) remains unclear. This study evaluated the therapeutic impact of third-line CTx after nanoliposomal irinotecan and fluorouracil combined with folinic acid (nal-IRI + 5-FU/LV) therapy as second-line CTx for UPC.</p><p><strong>Methods: </strong>Between June 2020 and May 2021, 104 patients who received nal-IRI + 5-FU/LV therapy as second-line CTx were retrospectively analyzed for post-discontinuation survival (PDS) and overall survival (OS). Comparisons were made between patients transitioning to third-line CTx and those receiving best supportive care (BSC), using a Cox proportional hazards model adjusted for patient background.</p><p><strong>Results: </strong>Of the cohort, 34 patients received third-line CTx, whereas 61 transitioned to BSC. The median OS from first-line CTx in the third-line CTx group was 18.0 months, with a median OS of 9.7 months from second-line CTx. Adjusted median PDS following second-line CTx was 6.5 months for the third-line CTx group compared to 2.3 months for the BSC group (adjusted hazard ratio 0.16; 95% confidence interval 0.08-0.32; P < 0.01).</p><p><strong>Conclusion: </strong>Third-line CTx should be actively considered for patients with UPC, as the approach may significantly extend survival in those who can tolerate the treatment.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1626689"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: The cellular and molecular basis of nutrition and lifestyle in cancer prevention and progression.","authors":"Adin Aggarwal, Maicon Roberto Kviecinski, Fabiana Ourique, Kenneth W Yip","doi":"10.3389/fonc.2025.1652368","DOIUrl":"https://doi.org/10.3389/fonc.2025.1652368","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1652368"},"PeriodicalIF":3.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}